Tenpoint Therapeutics launches with $70 million in Series A financing
Click Here to Manage Email Alerts
Key takeaways:
- Tenpoint Therapeutics has launched with a $70 million Series A financing.
- The company will develop cell-based therapeutics for degenerative ocular diseases.
Tenpoint Therapeutics has launched with a $70 million Series A financing, which will be used to develop regenerative medicine platforms to replace cells destroyed by inherited and age-related ocular diseases, according to a press release.
“From a patient perspective, we see tremendous opportunity,” Eddy Anglade, MD, CEO of Tenpoint, told Healio. “Our platform can mean the ability to not just stop the progression of disease, but to improve the functioning or replacement of cells that have been lost due to disease.”
The financing round included a new investment from British Patient Capital and funding from seed investors F-Prime Capital, Sofinnova Partners, Qiming Venture Partners USA, Eight Roads and the UCL Technology Fund.
Tenpoint is “advancing approaches to generate specialized ocular cell types both ex vivo and in vivo,” aiming to restore vision in people who have degenerative ocular diseases, according to the release.
“Part of the reason I went into ophthalmology is knowing that the patient can immediately experience the benefit of a successful therapeutic intervention, and with our platform, we see a new opportunity to fundamentally reshape what’s possible in the lives of people with ocular diseases,” Anglade said.
Collapse
Read more about
Click Here to Manage Email Alerts